EMOCHA MOBILE HEALTH, INC.
Video directly observed therapy (VDOT) platform delivered via smartphone for monitoring and promoting medication adherence
- Sector
- Digital health
- Headquarters
- Brooklandville, MD
- Founded
- 2013
- Latest Form D
- $14M, Apr 2023
- Total capital
- $35.1M
- Federal grants
- $11.7M
- 22 awards · 2015–2026
- Sector median 0 awards
- Private capital raised
- $23.4M
- 6 Form D · last Apr 2023
- 42 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- None on recordNo USPTO grants. Applications publish after 18 months.
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · ADHERE (Applying Directly observed therapy to HydroxyurEa to Realize Effectiveness)$50K
- Federal grantHealth and Human S · Phase II · ADHERE (Applying Directly observed therapy to HydroxyurEa to Realize Effectiveness)$649K
- Federal grantHealth and Human S · Phase II · Video observed therapy to enhance flexibility and reduce in-person visits for patients treated with methadone in a multi-site opioid treatment program$650K
- Federal grantHealth and Human S · Phase II · ADHERE (Applying Directly observed therapy to HydroxyurEa to Realize Effectiveness)$612K
- Federal grantHealth and Human S · Phase II · Video observed therapy to enhance flexibility and reduce in-person visits for patients treated with methadone in a multi-site opioid treatment program$659K
- Federal grantHealth and Human S · Phase II · Evaluation of a mobile app-based video Directly Observed Therapy (video DOT) intervention for medication adherence in pediatric heart transplant patients$837K
- Federal grantHealth and Human S · Phase II · ADHERE (Applying Directly observed therapy to HydroxyurEa to Realize Effectiveness)$643K
- Private capital raisedForm D · SEC · 6th filing$14M
- Private capital raisedForm D · SEC · 5th filing$2.1M
- Private capital raisedForm D · SEC · 4th filing$6.2M
- Private capital raisedForm D · SEC · 3rd filing$716K
- Private capital raisedForm D · SEC · 2nd filing$320K
- Private capital raisedForm D · SEC · 1st filing$50K
Show 15 earlier federal awards
- Federal grantHealth and Human S · Phase II · Video observed therapy to enhance flexibility and reduce in-person visits for patients treated with methadone in a multi-site opioid treatment program$654K
- Federal grantHealth and Human S · Phase II · Evaluation of a mobile app-based video Directly Observed Therapy (video DOT) intervention for medication adherence in pediatric heart transplant patients$839K
- Federal grantHealth and Human S · Phase II · Development and Evaluation of a Mobile Directly Observed Therapy Smartphone App for Immunosuppressive Adherence in Transplant Patients$728K
- Federal grantHealth and Human S · Phase I · Feasibility of mHealth technology-enabled service for remote observed therapy of methadone and COVID-19 screening for patients in an opioid treatment program$225K
- Federal grantHealth and Human S · Phase II · Development and Evaluation of a Mobile Directly Observed Therapy Smartphone App for Immunosuppressive Adherence in Transplant Patients$745K
- Federal grantHealth and Human S · Phase II · Development and Evaluation of a Mobile Directly Observed Therapy Smartphone App for Immunosuppressive Adherence in Transplant Patients$222K
- Federal grantHealth and Human S · Phase II · Development and Evaluation of Video-Based Directly Observed Therapy for Office-Based Treatment of Opioid Use Disorders with Buprenorphine$356K
- Federal grantHealth and Human S · Phase II · Development and Evaluation of Video-Based Directly Observed Therapy for Office-Based Treatment of Opioid Use Disorders with Buprenorphine$624K
- Federal grantHealth and Human S · Phase II · Evaluation of National Video Directly Observed Therapy Implementation$496K
- Federal grantHealth and Human S · Phase II · Development and Evaluation of Video-Based Directly Observed Therapy for Office-Based Treatment of Opioid Use Disorders with Buprenorphine$828K
- Federal grantHealth and Human S · Phase II · Evaluation of National Video Directly Observed Therapy Implementation$500K
- Federal grantHealth and Human S · Phase II · Development and Evaluation of Video-Based Directly Observed Therapy for Office-Based Treatment of Opioid Use Disorders with Buprenorphine$732K
- Federal grantHealth and Human S · Phase II · Development and Evaluation of Video-Based Directly Observed Therapy for Office-Based Treatment of Opioid Use Disorders with Buprenorphine$225K
- Federal grantHealth and Human S · Phase I · Development and Assessment of Video-Based Directly Observed Therapy for Tuberculosis$194K
- Federal grantHealth and Human S · Phase I · Development and Assessment of Video-Based Directly Observed Therapy for Tuberculosis$199K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Founders and team
Researcher links verified by same-company patents and grants- Sebastian SeiguerResearcherExecutive Officer, DirectorLinked by $11.7M in grants as PI
- Calbraith WheatonDirectorNamed in SEC Form D filings
- Daniel RocheDirectorNamed in SEC Form D filings
- Erica DrohanExecutive OfficerNamed in SEC Form D filings
- Jeff DaleyExecutive OfficerNamed in SEC Form D filings
- Matthew F. GorraExecutive OfficerNamed in SEC Form D filings
Show all 10 people
- Robert BollingerDirectorNamed in SEC Form D filings
- Theresa SextonDirectorNamed in SEC Form D filings
- Thomas CarrollDirectorNamed in SEC Form D filings
- Vincent CroweExecutive OfficerNamed in SEC Form D filings
What it has protected
No granted patents are on record.
USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.
Checked: USPTO granted patents and published applications · Oct 23, 2026
Regulatory activity · Digital health
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .